H. Hattori

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

Hiroki Sato, M. Wada, H. Jinno, 2018, BMC Cancer.

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

M. Wada, H. Jinno, Y. Kitagawa, 2018, BMC Cancer.